Histone deacetylase inhibitors down-regulate bcl-2 expression and induce apoptosis in t(14;18) lymphomas.
about
From cytopenia to leukemia: the role of Gfi1 and Gfi1b in blood formationTargeting histone deacetylases for cancer therapy: from molecular mechanisms to clinical implicationsMechanisms of Histone Deacetylase Inhibitor-Regulated Gene Expression in Cancer CellsNew and emerging HDAC inhibitors for cancer treatmentHistone acetyltransferases and histone deacetylases in B- and T-cell development, physiology and malignancySynergistic induction of apoptosis by HMG-CoA reductase inhibitor and histone deacetylases inhibitor in HeLa cellsSIRT3 and cancer: tumor promoter or suppressor?A phase 1 dose-escalation study of the oral histone deacetylase inhibitor abexinostat in combination with standard hypofractionated radiotherapy in advanced solid tumors.Nature and importance of follicular lymphoma precursors.A Novel Indication for Panobinostat as a Senolytic Drug in NSCLC and HNSCC.Targetome profiling and functional genetics implicate miR-618 in lymphomagenesisReal-time monitoring of nuclear factor kappaB activity in cultured cells and in animal models.Prognostic value of oncoprotein expressions in thyroid papillary carcinoma.SAHA and S116836, a novel tyrosine kinase inhibitor, synergistically induce apoptosis in imatinib-resistant chronic myelogenous leukemia cells.3, 3'5 Triiodo L thyronine induces apoptosis in human breast cancer MCF-7 cells, repressing SMP30 expression through negative thyroid response elements.Histone deacetylases regulate gonadotropin-releasing hormone I gene expression via modulating Otx2-driven transcriptional activity.Combination of sapacitabine and HDAC inhibitors stimulates cell death in AML and other tumour types.Selective repression of low-density lipoprotein receptor expression by SP600125: coupling of histone H3-Ser10 phosphorylation and Sp1 occupancyThe polycomb group protein BMI1 is a transcriptional target of HDAC inhibitors.Sp1 deacetylation induced by phorbol ester recruits p300 to activate 12(S)-lipoxygenase gene transcriptionRole of the cyclic AMP response element in the bcl-2 promoter in the regulation of endogenous Bcl-2 expression and apoptosis in murine B cells.Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents.The histone deacetylase inhibitor entinostat (SNDX-275) induces apoptosis in Hodgkin lymphoma cells and synergizes with Bcl-2 family inhibitors.Quantitative analysis of injury-induced anterior subcapsular cataract in the mouse: a model of lens epithelial cells proliferation and epithelial-mesenchymal transitionLead Induces Apoptosis and Histone Hyperacetylation in Rat Cardiovascular Tissues.Histone deacetylase inhibitor SAHA epigenetically regulates miR-17-92 cluster and MCM7 to upregulate MICA expression in hepatoma.Histone deacetylase inhibitors induce apoptosis in both Type I and Type II endometrial cancer cells.Novel HDAC inhibitors exhibit pre-clinical efficacy in lymphoma models and point to the importance of CDKN1A expression levels in mediating their anti-tumor responsePLGA-Loaded Gold-Nanoparticles Precipitated with Quercetin Downregulate HDAC-Akt Activities Controlling Proliferation and Activate p53-ROS Crosstalk to Induce Apoptosis in Hepatocarcinoma Cells.Metastasis-associated protein 1 drives tumor cell migration and invasion through transcriptional repression of RING finger protein 144AButyrate mediates decrease of histone acetylation centered on transcription start sites and down-regulation of associated genesHydrolysed inulin alleviates the azoxymethane-induced preneoplastic aberrant crypt foci by altering selected intestinal microbiota in Sprague-Dawley rats.Histone deacetylases as transcriptional activators? Role reversal in inducible gene regulation.Phosphorylation-mediated EZH2 inactivation promotes drug resistance in multiple myeloma.Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agentsThe effects of a histone deacetylase inhibitor on biological behavior of diffuse large B-cell lymphoma cell lines and insights into the underlying mechanisms.Inhibition of leukemic cells by valproic acid, an HDAC inhibitor, in xenograft tumors.Functional long-range interactions of the IgH 3' enhancers with the bcl-2 promoter region in t(14;18) lymphoma cellsHistone deacetylase inhibitors in lymphoma and solid malignancies.Glucose metabolism as a target of histone deacetylase inhibitors.
P2860
Q26786192-CDAC1075-1E90-4397-9B84-89E1D52F35F9Q26853394-B087AD65-972A-4A98-B1CD-5CEEEF9C734AQ27015931-29F24530-7F5B-48CA-B614-BB25584CFA97Q27022413-34AC5D20-CCC8-4A1F-B370-A1B4E9F44069Q28082536-6B999994-79A2-4D0F-8E87-004F62587662Q28383033-A18CAEDE-2408-4240-9B76-340E15493268Q28390097-405B021C-7C99-4C4A-AF6D-1CCD3C18F19CQ33437948-C6879B69-0E0B-4352-BAB6-0AAAE363EAD7Q33558757-AB34B37F-3FDA-4F85-A199-300AF829D007Q33689457-E0EDD3F6-9BC4-4A88-B974-2E8579E3C815Q33779176-3938F56E-EACD-45F4-9674-871E3088D92CQ33795121-2DB46492-65AF-461E-9097-8255EC29F9D1Q33890983-810B4DCF-5C6B-488C-8FE3-52CE38D16359Q33911230-5E2FFF3A-6EF8-4701-BFEF-96BD99195155Q33936933-35D1A9EA-7F2F-4C67-92D3-60A215F469DBQ34326508-E7DD7F05-30A7-4846-9B3C-A292E1DE3303Q34344158-5D582409-41BB-4CDA-9D95-9765BC37CF20Q34353731-730D37B5-2EA3-482F-B9F4-7EB801128E85Q34440758-E06DC2A7-2DA2-45AC-8779-6AAE6562CD75Q34519755-0DF5A0C7-0176-4224-B34B-A0A5FA35220EQ35131571-9A00EA61-2B9A-4F8B-8278-B1B1BC562BB0Q35214924-1F0C1117-5637-458F-8C25-12B166DCE73FQ35223868-6E60EC1B-E283-49C7-A1E9-2C2232FB8464Q35558466-D4219829-ADCC-4F8B-A374-4AC174DAB407Q35663628-DB4B2EE8-D6CF-4A3A-8B8E-7CF652CD8F13Q35677697-50A87344-7020-4F7B-A914-27BEC20A85A3Q35739692-9941A3FF-C62A-426C-B5DD-AF41D61725E1Q35741605-AD8B8621-3642-4B8F-9CB9-BEBC3C1F8E86Q35749718-66516F45-3D48-4E6D-B438-F3E51015AF87Q35774027-12705056-8909-409A-9CE1-9791AF9E959DQ35840700-02AB7C76-A461-4E81-806F-20192CDFD5ADQ35900047-111701E3-BE50-4659-A945-5C6AC0BC019AQ36224084-4318F213-A255-4369-BF5E-E57382F53BF5Q36335870-BD13459B-5A15-43B8-AD5A-E12A04BE7160Q36645808-9048269C-90A7-453C-AAF7-C7CA7EA6E0F8Q36926692-4CBF2039-62EC-462E-A58C-104853D84516Q36975828-1E56F172-2C31-4516-8603-2664206615A1Q37037146-5D5397D3-4C1A-4540-A60D-F2D783357D0BQ37118947-C0B0FF3A-4398-47E6-84DC-5BE841B54E58Q37125470-49C3667A-9161-4BAA-AD6B-F2BC2A754B2D
P2860
Histone deacetylase inhibitors down-regulate bcl-2 expression and induce apoptosis in t(14;18) lymphomas.
description
2005 nî lūn-bûn
@nan
2005 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի մարտին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Histone deacetylase inhibitors ...... optosis in t(14;18) lymphomas.
@ast
Histone deacetylase inhibitors ...... optosis in t(14;18) lymphomas.
@en
type
label
Histone deacetylase inhibitors ...... optosis in t(14;18) lymphomas.
@ast
Histone deacetylase inhibitors ...... optosis in t(14;18) lymphomas.
@en
prefLabel
Histone deacetylase inhibitors ...... optosis in t(14;18) lymphomas.
@ast
Histone deacetylase inhibitors ...... optosis in t(14;18) lymphomas.
@en
P2093
P2860
P1476
Histone deacetylase inhibitors ...... optosis in t(14;18) lymphomas.
@en
P2093
Caroline A Heckman
Linda M Boxer
P2860
P304
P356
10.1128/MCB.25.5.1608-1619.2005
P407
P577
2005-03-01T00:00:00Z